181 related articles for article (PubMed ID: 31621441)
1. Economic impact of severe asthma exacerbations in Spain: multicentre observational study.
Quirce S; Melero C; Huerta A; Uría E; Cuesta M
J Asthma; 2021 Feb; 58(2):207-212. PubMed ID: 31621441
[No Abstract] [Full Text] [Related]
2. Economic impact of severe asthma in Spain: multicentre observational longitudinal study.
Melero Moreno C; Quirce S; Huerta A; Uría E; Cuesta M
J Asthma; 2019 Aug; 56(8):861-871. PubMed ID: 30003827
[No Abstract] [Full Text] [Related]
3. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
Sicras-Mainar A; Capel M; Navarro-Artieda R; Nuevo J; Orellana M; Resler G
J Med Econ; 2020 May; 23(5):492-500. PubMed ID: 31958257
[No Abstract] [Full Text] [Related]
4. [Cost and management of asthma exacerbations in Spanish hospitals (COAX study in hospital services)].
Borderías Clau L; Zabaleta Murguionda M; Riesco Miranda JA; Pellicer Ciscar C; Hernández Hernández JR; Carrillo Díaz T; Lumbreras García G
Arch Bronconeumol; 2005 Jun; 41(6):313-21. PubMed ID: 15989888
[TBL] [Abstract][Full Text] [Related]
5. Measuring the cost of poor asthma control and exacerbations.
Sullivan PW; Ghushchyan VH; Campbell JD; Globe G; Bender B; Magid DJ
J Asthma; 2017 Jan; 54(1):24-31. PubMed ID: 27286240
[TBL] [Abstract][Full Text] [Related]
6. The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization.
Viinanen A; Lassenius MI; Toppila I; Karlsson A; Veijalainen L; Idänpään-Heikkilä JJ; Laitinen T
J Asthma; 2020 Oct; 57(10):1092-1102. PubMed ID: 31267775
[No Abstract] [Full Text] [Related]
7. Moderate symptom-based exacerbations as predictors of severe claims-based exacerbations in asthma.
Lane SJ; Petersen H; Seltzer JM; Blanchette CM; Navaratnam P; Allen-Ramey F; Fuhlbrigge A
J Asthma; 2013 Aug; 50(6):642-8. PubMed ID: 23514102
[TBL] [Abstract][Full Text] [Related]
8. Treatment, outcomes and costs of asthma exacerbations in Chilean children: a prospective multicenter observational study.
Herrera AM; Brand P; Cavada G; Koppmann A; Rivas M; Mackenney J; Sepúlveda H; Wevar ME; Cruzat L; Soto S; Pérez MA; León A; Contreras I; Alvarez C; Walker B; Flores C; Lezana V; Garrido C; Herrera ME; Rojas A; Andrades C; Chala E; Martínez RA; Vega M; Perillán JA; Seguel H; Przybyzsweski I
Allergol Immunopathol (Madr); 2019; 47(3):282-288. PubMed ID: 30595390
[TBL] [Abstract][Full Text] [Related]
9. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA.
Suruki RY; Daugherty JB; Boudiaf N; Albers FC
BMC Pulm Med; 2017 Apr; 17(1):74. PubMed ID: 28449686
[TBL] [Abstract][Full Text] [Related]
10. [Economic cost of treating the patient with asthma in Spain: the AsmaCost study].
Martínez-Moragón E; Serra-Batllés J; De Diego A; Palop M; Casan P; Rubio-Terrés C; Pellicer C;
Arch Bronconeumol; 2009 Oct; 45(10):481-6. PubMed ID: 19525051
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma.
Johansson G; Andreasson EB; Larsson PE; Vogelmeier CF
Pharmacoeconomics; 2006; 24(7):695-708. PubMed ID: 16802845
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain.
Vennera Mdel C; Valero A; Uría E; Forné C; Picado C
Clin Drug Investig; 2016 Jul; 36(7):567-78. PubMed ID: 27142072
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
[TBL] [Abstract][Full Text] [Related]
15. [Rate and characteristics of asthma exacerbations: the ASMAB I study].
Morell F; Genover T; Muñoz X; García-Aymerich J; Ferrer J; Cruz MJ
Arch Bronconeumol; 2008 Jun; 44(6):303-11. PubMed ID: 18559219
[TBL] [Abstract][Full Text] [Related]
16. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States.
Settipane RA; Kreindler JL; Chung Y; Tkacz J
Ann Allergy Asthma Immunol; 2019 Dec; 123(6):564-572.e3. PubMed ID: 31494235
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic burden of severe asthma: A French cohort study.
Nordon C; Grimaldi-Bensouda L; Pribil C; Nachbaur G; Amzal B; Thabut G; Marthan R; Aubier M;
Respir Med; 2018 Nov; 144():42-49. PubMed ID: 30366583
[TBL] [Abstract][Full Text] [Related]
18. Health Care Utilization and Direct Costs in Mild, Moderate, and Severe Adult Asthma: A Descriptive Study Using the 2014 South Korean Health Insurance Database.
Lee YJ; Kwon SH; Hong SH; Nam JH; Song HJ; Lee JS; Lee EK; Shin JY
Clin Ther; 2017 Mar; 39(3):527-536. PubMed ID: 28196623
[TBL] [Abstract][Full Text] [Related]
19. Asthma severity and medical resource utilisation.
Antonicelli L; Bucca C; Neri M; De Benedetto F; Sabbatani P; Bonifazi F; Eichler HG; Zhang Q; Yin DD
Eur Respir J; 2004 May; 23(5):723-9. PubMed ID: 15176687
[TBL] [Abstract][Full Text] [Related]
20. Costs of asthma in a cohort of Swiss adults: associations with exacerbation status and severity.
Schwenkglenks M; Lowy A; Anderhub H; Szucs TD
Value Health; 2003; 6(1):75-83. PubMed ID: 12535240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
